The science runs on capital and time
Life sciences run on long timelines and heavy capital. A drug or a device can take a decade and hundreds of millions of dollars to reach the market. The regulatory bar doesn’t move for anyone, no matter how good the science is.
That combination is unforgiving. You’re spending real money for years before you know whether the science works. Every month of runway is a month closer to an answer, or a month closer to a raise you didn’t plan for.
In that environment, books that lag put the science itself at risk. If the numbers are late or soft, the decisions built on them are late or soft too. The lab doesn’t feel it right away, but it feels it eventually.
Boards want one number: how long do we have
I’ve sat across the table from boards asking that same question in different forms. How long do we have. When does the money run out. What does the next twelve months actually cost.
They want an exact number. Defensible down to the month, because the next funding decision depends on it. A range doesn’t help them. A number they can stand behind does.
When the finance function can’t produce that number quickly, the board notices. And once a board starts doubting the numbers, it starts doubting everything else.
Where operating leverage comes from in this sector
Operating leverage here doesn’t come from cutting costs to the bone. It comes from a finance function that can model burn with precision, defend runway under real scrutiny, and close the books on time every cycle.
Precision on burn means you know what each program costs and what changes when timelines move. Defensible runway means you can walk a skeptical board through your assumptions and hold up. An on-time close means the numbers are ready when the decisions are.
Get those three right and the same capital goes further. Not because you spent less, but because you spent with confidence and timed it well. That’s the leverage.
The cost of a preventable gap
A trial that slips because of a preventable operational gap costs more than time. It costs credibility with investors who are already betting on uncertain science. They accepted the scientific risk. They didn’t sign up for the operational kind.
A late close signals something to a board that is watching every signal closely. It suggests the rest of the house might not be in order. Fair or not, that’s how it reads.
The operating rigor has to keep pace with the science. When it falls behind, it stops being a back-office problem and becomes a strategic one. That’s the gap worth closing before it opens.
Pairing scientific ambition with operating discipline
The companies that scale in this space pair scientific ambition with the same discipline on the finance side. Clean models. Real forecasts. A close cadence that never becomes the reason a raise stalls or a board loses confidence.
This is where Everest Advisors focuses. Everest has built its Life Sciences work around operators who have sat in the CFO seat at companies like Edwards, Ozlo, Plethy, Myochron, and Calyxt. They know what a life sciences board needs to see, and when they need to see it.
That experience matters because the timing is specific to this sector. Knowing a model is clean is one thing. Knowing which number a board will ask about before a raise, and having it ready, is another. Our Fractional & Interim CFO work is built for exactly that moment.
Let’s talk
If you have a board meeting or a raise on the calendar, that’s the time to get the finance side right. Not after the numbers are questioned, but before. We can help you walk in with runway you can defend and a close you don’t have to explain.
We’ve sat in your seat. Now we’re in your corner.
